COMMUNIQUÉS West-GlobeNewswire

Share buy-back week 11/2018
19/03/2018
Announcement 19 March 2018 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 3/2018 Coloplast has initiated the first part of the share buy-back programme totalling up [...]
Mustang Bio to Present at CAR-T Congress USA
19/03/2018
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO ), a Fortress Biotech (NASDAQ: FBIO ) Company focused on the development of novel immunotherapies based on proprietary chimeric [...]
Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin
19/03/2018
Favorable safety, tolerability, and efficacy observed in novel once-weekly echinocandin for difficult-to-treat invasive fungal infections Phase 3 studies for both treatment and prevention on track to start mid-2018 [...]
Stemline Therapeutics to Present at the Oppenheimer 28th Annual Healthcare Conference
19/03/2018
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML ), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein, M.D., [...]
Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018
19/03/2018
- Baseline demographics of TransCon Growth Hormone phase 3 heiGHt Trial presented - - Multiple ascending dose cohorts from TransCon PTH phase 1 clinical trial reinforced infusion-like profile over 24 hours - COPENHAGEN [...]
Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion
19/03/2018
CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced dosing of the [...]
Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY ER®
19/03/2018
AUSTIN, Texas, March 19, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE ), a drug development company, announced today that the U.S. Food and Drug Administration (FDA) will hold an Advisory Committee [...]
Axsome Therapeutics to Present at 17th Annual Needham Healthcare Conference
19/03/2018
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM ), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders [...]
The AdVance Study: a Landmark Natural History Study of Adenovirus in Allogeneic Hematopoietic Cell Transplant Shows Strong Correlation Between Disease Burden and Mortality Risk
19/03/2018
DURHAM, N.C., March 19, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX ), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data from AdVance, the first large, [...]
Motif Bio to present at upcoming investor and scientific conferences
19/03/2018
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company will present at [...]
VALNEVA Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15
19/03/2018
Valneva Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15 Phase I study (VLA15-101) primary endpoint met No safety concerns associated with VLA15 in any treatment group Encouraging [...]
VALNEVA publie des résultats intermédiaires de Phase I positifs pour son candidat vaccin contre la maladie de Lyme VLA15
19/03/2018
Valneva publie des résultats intermédiaires de Phase I positifs pour son candidat vaccin contre la maladie de Lyme VLA15 Critère d'évaluation principal de l'étude de Phase I (VLA15-101) atteint Aucun problème de [...]
MDxHealth (R): SelectMDx Liquid Biopsy Test for Prostate Cancer included in the 2018 European Association Urology Guidelines
19/03/2018
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION A significant milestone in MDxHealth's strategy to increase adoption of SelectMDx ® HERSTAL, BELGIUM and IRVINE, CA - 07:00 CEST, March 19, 2018 - MDxHealth SA ( [...]
MDxHealth (R) : Le test de biopsie liquide SelectMDx® pour le cancer de la prostate est inclus dans les directives 2018 de l'Association Européenne d'Urologie
19/03/2018
COMMUNIQUÉ DE PRESSE INFORMATION RÉGLEMENTÉE INFORMATION PRIVILEGIEE Une étape clé dans la stratégie de MDxHealth visant à accroître l'utilisation de SelectMDx HERSTAL, BELGIQUE et IRVINE, CA - 07 :00 CEST, le 19 mars [...]
Addex Shareholders Approved all Board Proposals at Extraordinary General Meeting
19/03/2018
Geneva, Switzerland, 19 March 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of oral allosteric modulators for neurological disorders, announced today that its shareholders approved all the proposals of [...]
Idorsia issues invitation to 2018 Annual General Meeting of Shareholders
19/03/2018
Allschwil, Switzerland - March 19, 2018 - Idorsia Ltd (SIX: IDIA) today issued the formal invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to [...]
Strongbridge Biopharma plc Announces Presentation of New Data Demonstrating That Levoketoconazole is a Potent Inhibitor of Human Enzymes Controlling Cortisol Synthesis
18/03/2018
~ Data Suggest Levoketoconazole, the Isolated 2S,4R Enantiomer of Ketoconazole, Accounts for Essentially All of the Inhibition by Ketoconazole of Cortisol Biosynthesis in Humans ~ ~ Results Presented at ENDO 2018, the [...]
Radius Health Presents Positive Data for the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection at ENDO 2018 Annual Meeting
17/03/2018
WALTHAM, Mass., March 17, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS ), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative [...]
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
16/03/2018
NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ: ABEO ), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life- [...]

Pages